Published in Q J Nucl Med Mol Imaging on April 01, 2011
Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology (2013) 1.23
Post-radioembolization yttrium-90 PET/CT - part 2: dose-response and tumor predictive dosimetry for resin microspheres. EJNMMI Res (2013) 1.14
EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging (2011) 1.13
Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS One (2013) 1.12
The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging (2014) 1.01
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging (2013) 0.99
SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging (2012) 0.95
Current and future treatments for hepatocellular carcinoma. World J Gastroenterol (2015) 0.92
Radioembolization of hepatic lesions from a radiobiology and dosimetric perspective. Front Oncol (2014) 0.91
Mitigation of Lethal Radiation Syndrome in Mice by Intramuscular Injection of 3D Cultured Adherent Human Placental Stromal Cells. PLoS One (2013) 0.88
18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging (2013) 0.87
Optimal design of anger camera for bremsstrahlung imaging: monte carlo evaluation. Front Oncol (2014) 0.86
Radioembolization of hepatocarcinoma with (90)Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. Eur J Nucl Med Mol Imaging (2015) 0.85
Clinical impact of (99m)Tc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with (90)Y-loaded microspheres. Eur J Nucl Med Mol Imaging (2015) 0.83
Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives. World J Gastroenterol (2015) 0.82
Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol (2013) 0.82
High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with (90) Y-loaded glass microsphere radioembolization. Liver Int (2016) 0.80
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. Eur J Nucl Med Mol Imaging (2015) 0.79
The role of SPECT/CT in radioembolization of liver tumours. Eur J Nucl Med Mol Imaging (2014) 0.79
Dosimetry for radiopharmaceutical therapy. Semin Nucl Med (2014) 0.79
Yttrium-90 microsphere radioembolization for hepatocellular carcinoma. Liver Cancer (2015) 0.78
The dosimetric importance of the number of 90Y microspheres in liver transarterial radioembolization (TARE). Eur J Nucl Med Mol Imaging (2014) 0.78
Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol (2015) 0.77
Personalized predictive lung dosimetry by technetium-99m macroaggregated albumin SPECT/CT for yttrium-90 radioembolization. EJNMMI Res (2014) 0.77
Radioembolization with (90)Y-loaded microspheres: high clinical impact of treatment simulation with MAA-based dosimetry. Eur J Nucl Med Mol Imaging (2015) 0.77
Radioembolisation of hepatocellular carcinoma patients using ⁹⁰Y-labelled microspheres: towards a diffusion of the technique? Eur J Nucl Med Mol Imaging (2011) 0.76
Increased absorbed liver dose in Selective Internal Radiation Therapy (SIRT) correlates with increased sphere-cluster frequency and absorbed dose inhomogeneity. EJNMMI Phys (2015) 0.75
A review of 3D image-based dosimetry, technical considerations and emerging perspectives in (90)Y microsphere therapy. J Diagn Imaging Ther (2015) 0.75
Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments. J Hepatocell Carcinoma (2014) 0.75
Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma (2016) 0.75
Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (1999) 4.04
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2008) 2.67
Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst (2001) 2.57
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology (2000) 2.15
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol (2006) 2.10
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol (1995) 2.09
Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev (2010) 2.09
Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med (1989) 1.94
Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med (2000) 1.93
Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma. Am J Transplant (2014) 1.77
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst (1995) 1.63
Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. Eur Respir J (2009) 1.62
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Protein HU binds specifically to kinked DNA. Mol Microbiol (1993) 1.56
Placement of long-term central venous catheters in outpatients: study of 134 patients over 24,596 catheter days. AJR Am J Roentgenol (1997) 1.55
Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer (1999) 1.54
Total rectal resection and complete mesorectum excision followed by coloendoanal anastomosis as the optimal treatment for low rectal cancer: the experience of the National Cancer Institute of Milano. Ann Surg Oncol (2000) 1.45
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucose. Eur J Nucl Med (1997) 1.42
Observation of a centrality-dependent dijet asymmetry in lead-lead collisions at sqrt[S(NN)] =2.76 TeV with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.41
Measurement of dijet azimuthal decorrelations in pp collisions at sqrt(s)=7 TeV. Phys Rev Lett (2011) 1.39
Stereotactic excisional breast biopsy performed by interventional radiologists using the advanced breast biopsy instrumentation system. Br J Radiol (1998) 1.39
How alternative are immunoassay systems employing non-radioisotopic labels? A comparative appraisal of their main analytical characteristics. Q J Nucl Med (1995) 1.39
[The scintigraphy of somatostatin receptors in gastroenteropancreatic neuroendocrine tumors]. Radiol Med (1997) 1.39
Rapid Flush Technique for Donor Hepatectomy: Safety and Efficacy of an Improved Method of Liver Recovery for Transplantation. Transplant Proc (1988) 1.37
FK 506 as a growth control factor. Transplant Proc (1990) 1.36
Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol (2000) 1.35
Determination of the strange-quark density of the proton from ATLAS measurements of the W→ℓν and Z→ℓℓ cross sections. Phys Rev Lett (2012) 1.34
Spindle cell lipoma of the hypopharynx. Dysphagia (2001) 1.34
Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology (2000) 1.32
Search for new particles in two-jet final states in 7 TeV proton-proton collisions with the ATLAS detector at the LHC. Phys Rev Lett (2010) 1.32
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol (2009) 1.30
Observation of associated near-side and away-side long-range correlations in sqrt[s(NN)]=5.02 TeV proton-lead collisions with the ATLAS detector. Phys Rev Lett (2013) 1.27
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol (2011) 1.24
Search for dark matter candidates and large extra dimensions in events with a photon and missing transverse momentum in pp collision data at sqrt[s]=7 TeV with the ATLAS detector. Phys Rev Lett (2013) 1.19
Failure of the phagocytic oxidative response to protect human monocyte-derived macrophages from infection by Leishmania donovani. J Immunol (1982) 1.19
Prolongation of pig-to-dog renal xenograft survival by modification of the inflammatory mediator response. Ann Surg (1987) 1.19
Childbearing after liver transplantation. Transplantation (1990) 1.19
Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med (1997) 1.18
Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg (1998) 1.17
Transplantation of the liver for metastatic endocrine tumors of the intestine and pancreas. Surg Gynecol Obstet (1989) 1.17
Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann Oncol (2001) 1.17
Isolation of the epithiospecifier protein from oil-rape (Brassica napus ssp. oleifera) seed and its characterization. FEBS Lett (2000) 1.17
Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol (2013) 1.16
Renal artery reconstruction for harvesting injuries in kidney transplantation with particular reference to the use of vascular allografts. Transpl Int (1988) 1.14
Search for a supersymmetric partner to the top quark in final states with jets and missing transverse momentum at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.13
Interstitial lung diseases in a lung cancer screening trial. Eur Respir J (2011) 1.13
Chemoembolization of hepatocellular carcinoma in patients who undergo liver transplantation. Radiology (1994) 1.12
Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol (2012) 1.12
Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med (1998) 1.11
Reappraisal of surgical treatment of small hepatocellular carcinomas in cirrhosis: clinicopathological study of resection or transplantation. Dig Dis Sci (1989) 1.10
Interaction of Leishmania donovani promastigotes with human monocyte-derived macrophages: parasite entry, intracellular survival, and multiplication. Infect Immun (1981) 1.10
The primary structure of UK114 tumor antigen. FEBS Lett (1996) 1.10
The use of standardized uptake values for assessing FDG uptake with PET in oncology: a clinical perspective. Nucl Med Commun (2004) 1.09
A randomized, controlled clinical trial to evaluate the effects of zinc sulfate on cancer patients with taste alterations caused by head and neck irradiation. Cancer (1998) 1.08
Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin Chem (1999) 1.07
Structure of L-aspartate oxidase: implications for the succinate dehydrogenase/fumarate reductase oxidoreductase family. Structure (1999) 1.07
Search for tb resonances in proton-proton collisions at √s=7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.07
Imaging with 131I-labeled monoclonal antibodies to a high-molecular-weight melanoma-associated antigen in patients with melanoma: efficacy of whole immunoglobulin and its F(ab')2 fragments. Cancer Res (1985) 1.06
Circulating immune complexes and rheumatoid factors in visceral leishmaniasis. J Infect Dis (1983) 1.05
Search for a light Higgs boson decaying to long-lived weakly interacting particles in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett (2012) 1.05
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Anticancer Res (2000) 1.04
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol (2007) 1.04
5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer (1998) 1.04
PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity. Br J Pharmacol (2010) 1.03
Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med (2001) 1.03
Stratifin, a keratinocyte specific 14-3-3 protein, harbors a pleckstrin homology (PH) domain and enhances protein kinase C activity. J Cell Sci (1995) 1.03
A clinicopathologic study of primary hepatic carcinoid tumors. Cancer (1990) 1.02
Nuclear medicine imaging of neuroendocrine tumours. Ann Oncol (2001) 1.02
Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer (1999) 1.02
The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro. Hepatology (1989) 1.01
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres. Q J Nucl Med Mol Imaging (2012) 1.01